In general, our findings, for the first time, define GDF6 as a negative regulator of cardiac hypertrophy and show that supplementation of GDF6 with viral/non-viral vectors or systemic administration with nanoparticles may be of great therapeutic interest for heart failure. This evidence concerns the gene GDF6 and heart failure.